Skip to content
The Policy VaultThe Policy Vault

Sprycel (dasatinib) — United Healthcare

Philadelphia chromosome-positive or BCR-ABL1-positive chronic myeloid leukemia

Initial criteria

  • Diagnosis of Philadelphia chromosome-positive or BCR-ABL1-positive chronic myeloid leukemia

Reauthorization criteria

  • Patient does not show evidence of progressive disease while on Sprycel therapy

Approval duration

12 months